{"filings":[{"id":98807,"accession_number":"0000078003-26-000053","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q1 revenue $14.5B (+2% op); adj EPS $0.75 (-18%); reaffirms FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.45B, up 2% operationally; ex-COVID products grew 7% op; launched/acquired products up 22% op.","Reported diluted EPS $0.47, adjusted $0.75 vs $0.92 in Q1 '25 (-18%).","Reaffirmed FY26 revenue guidance $59.5-62.5B and adj EPS $2.80-3.00.","Positive Phase 3 readouts for Elrexfio (RRMM), Padcev (MIBC), Talzenna+Xtandi, Lyme vaccine 73-75% efficacy.","Exited ViiV Healthcare for $1.875B; Vyndamax patent settlement extends to 2031; GLP-1 collaboration in China for ecnoglutide."],"consensus_eps_estimate":null,"consensus_eps_actual":0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":14451000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98806,"accession_number":"0000078003-26-000044","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pfizer annual meeting: all 12 directors elected, stock plan approved, independent chair proposal fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 12 director nominees elected; Joseph Echevarria received highest 'against' votes with 612.4M (16.4% of votes cast).","KPMG ratified as independent auditor for 2026 fiscal year with 93% of votes for (4.16B for, 322M against).","Pfizer 2019 Stock Plan amendment approved with 86.9% of votes cast (3.23B for, 305M against).","Advisory say-on-pay on 2026 executive compensation approved with 87.9% of votes cast (3.10B for, 424M against).","Shareholder independent chair proposal rejected; 28.8% of votes cast in favor (1.02B for, 2.51B against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114479,"accession_number":"0000078003-26-000005","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer reports FY2025 revenue $62.6B, adj. EPS $3.22; reaffirms FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $62.6B (-2% operational); non-COVID portfolio +6% operational.","FY2025 reported diluted EPS $1.36; adjusted diluted EPS $3.22 (+4% YoY).","Q4 2025 revenue $17.6B (-1%); Q4 reported LPS ($0.29); adj. diluted EPS $0.66.","Completed Metsera acquisition (~$7B); ViiV stake sale for $1.875B; reaffirms FY2026 revenue guidance $59.5-62.5B, adj. EPS $2.80-3.00."],"consensus_eps_estimate":null,"consensus_eps_actual":1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":62579000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130857,"accession_number":"0000078003-25-000167","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pfizer revises FY2025 revenue to ~$62B (from $61-64B), provides FY2026 EPS guidance $2.80-3.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revised FY2025 revenue guidance to ~$62.0B from prior $61-64B; reaffirmed adjusted diluted EPS $3.00-3.15.","FY2026 revenue guidance $59.5-62.5B; adjusted diluted EPS $2.80-3.00; tax rate ~15% vs ~11%.","COVID-19 product revenues ~$5.0B in 2026 (vs ~$6.5B in 2025); LOE impact ~$1.5B.","Adjusted SI&A $12.5-13.5B, R&D $10.5-11.5B in 2026; investing in PD-1 x VEGF bispecific and Metsera programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130856,"accession_number":"0001193125-25-291406","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pfizer completes $6.0 billion offering of notes due 2027-2065","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M Floating Rate Notes due 2027, $1B 3.875% Notes due 2027, $1B 4.200% Notes due 2030","Issued $1.25B 4.500% Notes due 2032, $1.25B 4.875% Notes due 2035, $500M 5.600% Notes due 2055","Issued $500M 5.700% Notes due 2065 for total aggregate principal of $6.0 billion","Underwriters include Citigroup, Deutsche Bank, J.P. Morgan, Mizuho Securities"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130855,"accession_number":"0000078003-25-000159","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pfizer completes $7B acquisition of Metsera, including contingent milestones up to $20.65/sh","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enterprise value ~$7.0B; each Metsera share converted into $65.60 cash at closing.","Plus up to $20.65/sh in contingent value rights tied to three FDA/clinical milestones.","Milestones: Phase 3 start for MET-097i+MET-233i combo ($4.60/sh), FDA nod for monthly MET-097i ($6.40/sh), FDA nod for combo ($9.65/sh).","Acquisition aimed at bolstering Pfizer's obesity pipeline with GLP-1 receptor antagonist + amylin analog."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130854,"accession_number":"0000078003-25-000149","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q3 adj EPS $0.87 beat; raises FY adj EPS guidance to $3.00-$3.15; sues Novo Nordisk over Metsera","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $16.7B (-7% operational YoY); reported EPS $0.62, adj EPS $0.87.","Raises FY2025 adj diluted EPS guidance to $3.00-$3.15 from $2.90-$3.10; reaffirms revenue $61-64B.","Reached landmark agreement with U.S. government on drug pricing; sues Novo Nordisk for tortious interference over Metsera acquisition.","Inclacumab fails Phase 3 THRIVE-131 in sickle cell disease; $1.35B IPR&D charge for 3SBio deal.","Expects ~$7.2B net cost savings by 2027; no share repurchases planned; $7.3B dividends paid YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":45022000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147424,"accession_number":"0000078003-25-000136","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q2 2025 revenue $14.7B (+10% YoY); raises FY adjusted EPS guidance to $2.90-$3.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported diluted EPS $0.51; adjusted diluted EPS $0.78, up 30% YoY.","FY 2025 revenue guidance reaffirmed at $61B-$64B; adjusted EPS guidance raised by $0.10 to $2.90-$3.10.","Vyndaqel family revenue up 21% operationally; Comirnaty +95%; Paxlovid +71%; Padcev +38%; Eliquis +6%.","Completed $1.25B upfront in-licensing of 3SBio's SSGJ-707; one-time ~$0.20 EPS impact in Q3.","On track for $7.2B net cost savings by end of 2027; capital allocation includes $4.9B dividends in H1."],"consensus_eps_estimate":null,"consensus_eps_actual":1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":28367000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166056,"accession_number":"0001193125-25-122480","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pfizer subsidiary completes €3.3B debt offering in four tranches","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €750M 2.875% notes due 2029, €1B 3.250% notes due 2032, €750M 3.875% notes due 2037, €800M 4.250% notes due 2045.","Notes are fully and unconditionally guaranteed by Pfizer on a senior unsecured basis.","Offering completed on May 19, 2025 under existing shelf registration statement.","The debt raise adds €3.3B in long-term fixed-rate liabilities across maturities from 2029 to 2045."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166055,"accession_number":"0000078003-25-000111","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Pfizer Q1 revenues $13.7B (-8% YoY), adjusted EPS $0.92 (+12%); reaffirms FY2025 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 revenues $13.7B, down 8% YoY; reported diluted EPS $0.52 (down 5%), adjusted diluted EPS $0.92 (up 12%).","Reaffirms FY2025 guidance: revenue $61-$64B, adjusted diluted EPS $2.80-$3.00, with no share buybacks anticipated.","Expands cost realignment: additional $1.2B net savings by 2027 (SI&A focus) plus $500M R&D reinvestment by 2026; one-time costs $1.6B and $600M respectively.","Paxlovid revenue fell $1.5B operationally (75% drop); Vyndaqel family grew 33% operationally; Comirnaty up 62% operationally.","Paid $2.4B in cash dividends ($0.43/shr) in Q1; gross leverage below previously stated target; $3.3B remaining buyback authority."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166054,"accession_number":"0000078003-25-000109","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pfizer annual meeting results: all director nominees elected, say-on-pay passed with 54.7% approval","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 13 director nominees elected; highest support for Scott Gottlieb (3.50B for), lowest for Joseph Echevarria (3.17B for).","Ratification of KPMG as auditor for 2025 approved: 4.22B votes for (93.3% of votes cast).","Advisory say-on-pay approved with 54.7% support (1.95B for, 1.61B against); significant opposition noted.","Two shareholder proposals defeated: golden parachute vote (9.5% for) and religious discrimination report (2.0% for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183580,"accession_number":"0000078003-25-000017","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q4/FY2024 rev $63.6B (+7% op); adj EPS $3.11; reaffirms 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenues $63.6B (+7% operational); excluding COVID products, up 12% operationally.","FY2024 reported diluted EPS $1.41; adjusted diluted EPS $3.11. Q4 adjusted EPS $0.63.","Reaffirms FY2025 guidance: revenue $61-$64B, adjusted diluted EPS $2.80-$3.00.","On track for ~$4.5B net cost savings by end 2025; $1.5B from Manufacturing Optimization by 2027.","Positive Phase 3 BREAKWATER for Braftovi in mCRC; sold ~$3B Haleon stake; Boshoff named CSO."],"consensus_eps_estimate":null,"consensus_eps_actual":1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":63627000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200164,"accession_number":"0000078003-24-000195","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pfizer provides 2025 revenue guidance $61-64B, adj. EPS $2.80-3.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full-year 2025 revenue guidance range of $61.0 to $64.0 billion, with operational growth approximately flat to 5% year-over-year.","Full-year 2025 adjusted diluted EPS guidance range of $2.80 to $3.00, reflecting operational growth of 10% to 18%.","Achieved goal of $4.0 billion in net cost savings through 2024; expects an additional $500 million in savings in 2025.","First phase of manufacturing optimization program on track to deliver initial net cost savings in latter part of 2025.","Reaffirmed full-year 2024 guidance: revenue $61-64B, adjusted EPS $2.75-2.95."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200163,"accession_number":"0000078003-24-000188","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q3 revenue $17.7B (+32% YoY); raises FY 2024 guidance on revenue and EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenues of $17.7B, operational growth +32% YoY; ex-Paxlovid/Comirnaty revenue up 14% operationally.","Reported diluted EPS $0.78 vs. ($0.42) in Q3 2023; adjusted diluted EPS $1.06 vs. ($0.17).","Raised FY 2024 revenue guidance to $61-64B (from $59.5-62.5B) and adjusted EPS to $2.75-2.95 (from $2.45-2.65).","Paxlovid revenue $2.7B (+$2.5B YoY); Comirnaty revenue $1.4B (+9% operational).","Cost reduction program on track for at least $5.5B net savings; $4B expected by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":45864000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200162,"accession_number":"0000078003-24-000185","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pfizer elects former Vanguard CEO Tim Buckley to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mortimer J. Buckley elected to Pfizer Board effective Oct 10; appointed to Audit and Governance committees.","Buckley served as Vanguard Chairman & CEO from 2018 until retirement in 2024; previously CIO.","Board now has 14 directors, 13 of whom are independent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216183,"accession_number":"0000078003-24-000155","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q2 adj EPS $0.60, revenue $13.3B; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $13.3B, +2% YoY (+3% operational); non-COVID revenue grew 14% operationally.","Adjusted diluted EPS $0.60, vs $0.67 prior year; includes $1.3B one-time manufacturing optimization costs.","Raised FY2024 revenue guidance to $59.5-$62.5B (from $58.5-$61.5B) and adjusted EPS to $2.45-$2.65 (from $2.15-$2.35).","Launched Manufacturing Optimization Program targeting ~$1.5B cost savings by end of 2027; one-time costs ~$1.7B.","CSO Dr. Mikael Dolsten to depart; successor search underway."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":28162000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216182,"accession_number":"0000078003-24-000144","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Pfizer extends vesting and performance periods on 2022/2023 long-term equity awards for ~9,000 employees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to 9,000 active employees eligible, including CEO Bourla, CFO Denton, and other named executives.","2022 and 2023 TSRUs can be extended for 2 years: settlement now Feb 2029 (2022 grants) and Feb 2030 (2023 grants).","2022 and 2023 PSAs can get a 2-year performance period extension, vesting in 2027 and 2028 respectively.","Modifications aim to restore retention value after COVID-related stock price decline reduced award incentive.","Election is voluntary via a forthcoming tender offer; all other award terms remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216181,"accession_number":"0000078003-24-000130","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pfizer begins external search for successor to Chief Scientific Officer Mikael Dolsten","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CSO and President of R&D Mikael Dolsten to step down after over 15 years; external search launched.","Dr. Dolsten will stay in current role until successor is appointed, at least through Feb 28, 2025.","No successor named; transition process formally announced on July 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216180,"accession_number":"0000078003-24-000127","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cyrus Taraporevala elected to Pfizer's Board of Directors effective June 27, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Taraporevala, former President & CEO of State Street Global Advisors (2017-2022), joins Board.","Appointed to Audit Committee and Compensation Committee immediately.","Also serves on boards of Shell plc and Bridgepoint Group plc.","Background includes roles at Fidelity, BNY Mellon, Legg Mason, Citigroup, and McKinsey."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235717,"accession_number":"0000078003-24-000113","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Pfizer launches multi-year COGS reduction program; targets $1.5B savings by 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First phase of cost-reduction program expected to deliver ~$1.5B savings by end of 2027.","One-time costs estimated at ~$1.7B, primarily severance and implementation costs.","Costs recorded mostly in 2024; cash outlays expected in 2025 and 2026.","Program includes operational efficiencies, network structure changes, and portfolio enhancements.","Savings realization expected to begin in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235716,"accession_number":"0000078003-24-000103","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q1 revenue $14.9B (-20% YoY); adj. EPS $0.82; raises FY adj. EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $14.9B, operational decline 19% YoY; ex-COVID products grew 11% operationally.","Reported diluted EPS $0.55; adjusted diluted EPS $0.82 (includes $0.11 favorable Paxlovid return adjustment).","Full-year 2024 revenue guidance reaffirmed at $58.5-$61.5B; adjusted EPS guidance raised to $2.15-$2.35.","Cost realignment program on track to deliver at least $4 billion net cost savings by end of 2024.","Notable approvals: Beqvez (hemophilia B) FDA approval, Prevenar 20 (pediatrics) EU approval, Tivdak full FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":14879000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235715,"accession_number":"0000078003-24-000101","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pfizer shareholders elect all 12 board nominees, approve stock plan and say on pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected; Albert Bourla received 3.42B votes for (92.6% of votes cast).","Ratification of KPMG as auditor for 2024 approved with 4.32B votes for (93.9% of votes cast).","Amended and Restated 2019 Stock Plan approved with 3.41B votes for (92.5% of votes cast, excluding broker non-votes).","Advisory say-on-pay proposal approved with 3.36B votes for (91.4% of votes cast).","Shareholder proposals on independent board chair, political congruency report, and corporate contributions report all failed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253479,"accession_number":"0000078003-24-000017","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer posts FY2023 revenue $58.5B, adj EPS $1.84; reaffirms FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 revenues $58.5B, down 41% operationally; reported diluted EPS $0.37, down 93%; adjusted diluted EPS $1.84, down 72%.","Q4 2023 revenues $14.2B, down 42% operationally; reported diluted LPS $(0.60), adjusted EPS $0.10.","Ex-COVID products grew 7% operationally in FY2023 (8% in Q4); Seagen acquisition closed Dec 2023 for $44B.","FY2024 revenue guidance $58.5-61.5B, adj EPS $2.05-2.25; expects $4B cost savings by end 2024.","No share repurchases planned in 2024; $9.2B dividends paid in FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":58496000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253478,"accession_number":"0000078003-24-000006","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pfizer warns shareholders of unsolicited mini-tender offer at below-market price","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["TRC Capital offers $27.35/share for up to 4M shares, 4.4% below Dec 27 close of $28.61.","Offer covers only ~0.071% of outstanding shares; Pfizer does not endorse it.","Stockholders who tendered can withdraw before offer expires Jan 30, 2024 at 12:01 a.m. ET.","SEC cautions that mini-tender offers may catch investors off guard; Pfizer advises no action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270945,"accession_number":"0001193125-23-294930","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Pfizer completes $43B acquisition of Seagen at $229/share, expanding oncology portfolio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pfizer acquired Seagen for $229 per share in cash, total enterprise value of ~$43 billion.","Acquisition adds Seagen's four in-line ADC medicines (ADCETRIS, PADCEV, TIVDAK, TUKYSA) to Pfizer's oncology portfolio.","Pfizer's oncology pipeline doubles to 60 programs; now includes over 25 approved medicines across more than 40 indications.","To address FTC concerns, Pfizer irrevocably donates U.S. royalties from Bavencio (avelumab) to American Association for Cancer Research.","Pfizer expects oncology to be a significant growth driver and contribute to near- and long-term financial goals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270940,"accession_number":"0001193125-23-295562","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K/A","filed_at":"2023-12-14T23:59:59+00:00","items":["2.02","2.01","7.01","9.01"],"status":"ready","headline":"Pfizer completes $43B acquisition of Seagen; Seagen becomes wholly owned subsidiary","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Dec 14, 2023; $229 per share in cash for total enterprise value approx. $43 billion.","Adds Seagen's four approved medicines (ADCETRIS, PADCEV, TIVDAK, TUKYSA) and ADC technology.","Pfizer's oncology pipeline doubled to 60 programs across multiple modalities.","To address FTC concerns, Pfizer irrevocably donated U.S. royalty rights from Bavencio (avelumab) to AACR.","Pfizer's oncology portfolio now includes over 25 approved medicines and biosimilars across >40 indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270944,"accession_number":"0000078003-23-000120","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pfizer guides FY2024 rev $58.5-61.5B, adj EPS $2.05-2.25; Seagen closing Dec 14","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue guidance $58.5-$61.5B; includes ~$8B from Comirnaty/Paxlovid and ~$3.1B from Seagen.","FY2024 adjusted diluted EPS guidance $2.05-$2.25; includes ~$0.40 dilution from Seagen.","Cost realignment program now expected to deliver at least $4.0B annual net savings by end 2024.","Excluding COVID products and Seagen, operational revenue growth 3%-5% YoY.","Seagen acquisition has received all regulatory approvals; closing expected Dec 14, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270943,"accession_number":"0000078003-23-000118","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pfizer expects to close Seagen acquisition on Dec 14; all regulatory approvals received","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Expects to close Seagen acquisition on Dec 14, 2023 after receiving all required regulatory approvals.","Irrevocably donates U.S. royalties from Bavencio (avelumab) sales to AACR to address FTC concerns.","Creates Pfizer Oncology Division led by Chris Boshoff; splits non-oncology into U.S. and International divisions led by Aamir Malik and Alexandre de Germay.","Angela Hwang leaves role as Chief Commercial Officer; will serve as advisor to CEO during transition.","Plans analyst call on Dec 13 to discuss acquisition, new organization, and provide FY2024 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}